The role of biomarkers in cancer diagnosis, prognosis, and treatment is rapidly evolving. As knowledge about the molecular biology of cancer continues to expand, identification of actionable biomarkers (biological changes occurring in the body such as protein expression, receptors, hormones, enzymes, as well as both somatic and germline genetic mutations) continues to increase. Biomarkers (also referred to as "tumor markers" or "molecular markers") have enabled researchers to better understand cancer subtypes and to develop targeted anti-cancer therapies. The National Cancer Institute has compiled a list of commonly used biomarkers, their associated cancer types, and how the marker is used. View the list.
This environmental scan provides an overview of the current landscape of biomarker testing at cancer programs, challenges or barriers to implementing testing recommendations, efforts by ACCC and others to-date, and possible solutions toward creating operational efficiencies in testing.
Download Environmental Scan
Presented at the 2020 ASCO Virtual Scientific Program
To support quality improvement (QI) projects in mCRC (metastatic colorectal cancer), the Association of Community Cancer Centers (ACCC) has partnered with Pfizer Global Medical Grants to award more than $1 million in funding to QI projects that are aimed at improving the integration of biomarker testing in personalized treatment selection for patients with mCRC.
Through this educational program, ACCC will identify and disseminate examples of effective practices and tools for developing, implementing, and assessing operational pathways for molecular testing for eligible patients with NSCLC.